Loading organizations...
Inversi is an organization for which comprehensive operational specifics, including its core business activities and primary geographic headquarters, are presently unavailable through public channels. Detailed insights into its specific business model, target market sectors, and identified customer base remain undisclosed in all accessible records. The current scale of Inversi's operations, encompassing any reported funding rounds, assets under management, valuation metrics, employee count, or user statistics, has not been publicly documented or verified. Furthermore, no recognizable lead investors, significant portfolio companies, or prominent customers directly associated with Inversi have been publicly identified or linked to its operations. Publicly accessible data also lacks specific details concerning its precise founding year or the names of its principal founders. The organization's overall market positioning, strategic focus, and any recent developments are not ascertainable from currently available public sources, preventing a comprehensive profile.
Inversi has 1 tracked investment across 1 company. The latest tracked deal is $21.8M Other Equity in Medlumics in February 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2021 | Medlumics | $21.8M Other Equity | Josep L.l. Sanfeliu | Olivier Litzka, Caixa Capital Risc, Cdti, Innogest, Peter Neubeck, Diego Braguglia |